Presented By:
Dr. Jared Aulcair

Speaker Biography:
Jared R. Auclair is currently the Associate Dean of Professional Program and Graduate Affairs in the College of Science at Northeastern University and Associate Teaching Professor in the department of chemistry and chemical biology. In addition, Dr. Auclair is the Director of the Biopharmaceutical Analysis Laboratory (BATL), the Asia-Pacific Economic Cooperation Center of Regulatory Excellence in Biotherapeutics and Advanced Therapies and oversees the International Council for Harmonisation training. Lasting, Prof. Auclair serves as the Technical Supervisor for the Life Science Testing Center at Northeastern University, which is a state and CLIA-certified lab. Dr. Auclair collaborate with both academic researchers, industry, and government in the area of biopharmaceutical development and analysis. He has expertise in mol. biology, protein biochemistry, analytical chemistry, protein crystallography, and biological mass spectrometry; and is interested in use inspired research for the biotechnology industry.

Webinar:
The Impact of SARS-CoV-2 Genomic Surveillance Locally, Nationally, and Globally

Webinar Abstract:
Emergence of genetic mutations within the SARS-CoV-2 genome that may enhance transmissibility, increase symptom severity or improve the virus’s ability to evade immunity produced by current vaccines, have raised concerns around the world. Learn from two colleagues that have pivoted lab efforts to enable SARS-CoV-2 mutation surveillance at a local and national level.



Testing and Surveillance of SARS-CoV-2 Variants to Enable Safe Return to On-campus Learning


In March of 2020, like other Universities, Northeastern University (Boston, MA) moved all instruction online and shortly there after closed campus down. Almost immediately after the University started to plan for its reopening in Fall of 2022. In this presentation, we will briefly look at Northeastern Universities response to COVID-19 through testing as well as the importance of genomic surveillance as the number of variants reported increases.


SARS CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom


Mandatory Day 2 and Day 8 PCR testing of international arrivals has been recently introduced by the UK Government to mitigate against the cross-border transmission of high risk SARS-CoV-2 variants. All positive Day 2 samples with cycle threshold (Ct) values of 30 (defined as equivalent to ~10,000-1,000 viral genome copies/ml) must undergo genomic sequencing. Oncologica is a participant in this testing program and utilizes a novel integrated test and sequence workflow to detect and identify variants. Here we have conducted a retrospective analysis of SARS-CoV-2 test data to determine the prevalence and variant type entering the UK.

Earn PACE Credits:
1. Make sure you're a registered member of LabRoots (https://www.labroots.com/ms/webinar/secure-discovery)
2. Watch the webinar on the LabRoots Website (https://www.labroots.com/credit/pace-credits/5881)
3. Click Here to get your PACE credits (Expiration date – MAY 05, 2023): (https://www.labroots.com/credit/pace-credits/5730)

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc